Entities / Company
VOR.
company in the Czech Republic
- Reports this week
- 0
- Active events
- 0
- Connections
- 23
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
Gone quiet
No new reports in 90+ days-
Vor Bio agreed to file a registration statement with the Securities and Exchange Commission on June 26, 2025.Speculative1 report
-
VOR licensed telitacicept from RemeGen and appointed Jean-Paul Kress as CEO and Chairman of the company.Speculative1 report
-
Upgrade from HC Wainwright drove share surge at VOR on July 1, 2025.Speculative1 report
-
VOR granted stock options to Jean-Paul Kress for commencing employment on July 2, 2025.Speculative1 report
-
VOR appointed Sandy Mahatme as CFO and CBO to support company growth.Some support1 report
-
VOR partnered with RemeGen for telitacicept licensing.Well supported6 reports
-
VOR granted stock options to Qing Zuraw, M.D. for commencing employment on July 19, 2025.Some support1 report
-
The largest shareholder of VOR holds 32% of shares outstanding as of July 2025.Some support1 report
-
Michel Detheux's company partnered with GSK, and Detheux joined Vor's board of directors in July 2025.Some support1 report
-
PowerFleet and VOR are benefiting from Trump-era tariffs and onshoring, with an AI module helping lower VOR time.Some support1 report
-
VOR, a biotechnology company, is based in Cambridge, Massachusetts.Some support2 reports
-
Jean-Paul Kress was appointed CEO and Chairman of the Board of VOR.Some support5 reports
No events began in the chosen period. Widen it, or reset.
Around VOR this week
News at the entities that move VOR most-
Jefferies Financial Group OperationalApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves VOR
-
SEC StructuralDHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Moves VOR
-
Nasdaq StructuralAppLovin stock is traded on Nasdaq, and both AppLovin and Trade Desk operate in the competitive digital advertising technology landscape.Moves VOR
-
Cambridge Shared contextA book featuring Alice Hoffman is set in Cambridge during the 1950s.Moves VOR
-
FDA Mentioned togetherGeneric medicine services are seeking approval for launch from the FDA.Moves VOR
Connections
The 7 strongest of 23, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Jean-Paul Kress Structural
VOR employs Jean-Paul Kress as CEO and Chairman of the Board.
-
RemeGen Co., Ltd. Operational
RemeGen and VOR maintain an active operational partnership through exclusive licensing and clinical collaboration.
-
Jefferies Financial Group Operational
Jefferies Financial Group's analyst ratings and reports directly influence VOR's company valuation and market perception.
-
Nasdaq Structural
VOR is a publicly traded company whose market presence is dependent on the Nasdaq electronic exchange infrastructure.
-
SEC Structural
VOR is subject to formal regulatory oversight by the SEC regarding corporate disclosures and sales.
-
Cambridge Shared context
VOR is a biotechnology company based in Cambridge, Massachusetts.
-
FDA Mentioned together
No direct evidence linking FDA and VOR was found in the provided timeline.
History
Events by the month they beganJuly 2026
2 eventsJune 2026
12 events- Vor Bio agreed to file a registration statement with the Securities and Exchange Commission on June 26, 2025.
- VOR licensed telitacicept from RemeGen and appointed Jean-Paul Kress as CEO and Chairman of the company.
- Upgrade from HC Wainwright drove share surge at VOR on July 1, 2025.
- VOR granted stock options to Jean-Paul Kress for commencing employment on July 2, 2025.
- VOR appointed Sandy Mahatme as CFO and CBO to support company growth.
- VOR partnered with RemeGen for telitacicept licensing.
- VOR granted stock options to Qing Zuraw, M.D. for commencing employment on July 19, 2025.
- The largest shareholder of VOR holds 32% of shares outstanding as of July 2025.
- Michel Detheux's company partnered with GSK, and Detheux joined Vor's board of directors in July 2025.
- PowerFleet and VOR are benefiting from Trump-era tariffs and onshoring, with an AI module helping lower VOR time.
- VOR, a biotechnology company, is based in Cambridge, Massachusetts.
- Jean-Paul Kress was appointed CEO and Chairman of the Board of VOR.